Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden

Einarson, Thomas R.; Vicente, Colin; Zilbershtein, Roman; Piwko, Charles; Bø, Christel N.; Pudas, Hanna; Jensen, R.; Hemels, M.

doi:10.3109/08039488.2013.852243

Cited by 23 publications

(28 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent publications have shown PP1M to be either economically dominant (better effectiveness for lower cost) or cost effective [17,19,57–61] versus risperidone microspheres, olanzapine pamoate, haloperidol decanoate, zuclopentixol decanoate or a selection of oral antipsychotics.…”

Section: Discussionmentioning

confidence: 99%

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study

Decuypere¹,

Sermon

Geerts

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Achieving greater continuation of treatment is a key element to improve treatment outcomes in schizophrenia patients. However, reported treatment continuation can differ markedly depending on the study design. In a retrospective setting, treatment continuation remains overall poor among patients using antipsychotics. This study aimed to document the difference in treatment continuation between four long-acting injectable antipsychotics based on the QuintilesIMS LRx databases, national, longitudinal, panel based prescription databases of retail pharmacies, in the Netherlands and Belgium. Paliperidone palmitate once monthly, risperidone microspheres, haloperidol decanoate, and olanzapine pamoate were studied. This study demonstrated significantly higher treatment continuation of paliperidone palmitate once monthly compared to risperidone microspheres (p-value<0,01) and haloperidol decanoate (p-value<0,01) in both countries, a significantly higher treatment continuation of paliperidone palmitate once monthly compared to olanzapine pamoate in the Netherlands (p-value<0,01), and a general trend towards better treatment continuation versus olanzapine pamoate in Belgium. Analysing the subgroup of patients without previous exposure to long-acting antipsychotic treatment revealed the positive impact of previous exposure on treatment continuation with a subsequent long acting treatment. Additionally, the probability of restarting the index therapy was higher among patients treated with paliperidone palmitate once monthly compared to patients treated with risperidone microspheres and haloperidol decanoate. The data source used and the methodology defined ensured for the first time a comparison of treatment continuation in a non-interventional study design for the four long-acting injectable antipsychotics studied.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study

Decuypere¹,

Sermon

Geerts

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The high rate of polypharmacy may indicate that available pharmacological treatments and treatment guidelines are still far from meeting all needs (55). Alternatively, issues such as compliance may be a problem with additional treatments added before exploring these factors further and potentially switching formulations or modes of administration (56,57).…”

Section: Introductionmentioning

confidence: 99%

Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future

Mahmood

Hussain

Rehman

et al. 2018

Current Medical Research and Opinion

View full text Add to dashboard Cite

There has been an appreciable increase in antipsychotic utilization in recent years in Pakistan, especially atypical antipsychotics, with little polypharmacy. Ongoing utilization of typical antipsychotics may be due to comorbidities such as diabetes and cardiovascular disease. Issues of international non-proprietary name prescribing need investigating along with the high number of medicines per encounter and gender inequality.

show abstract

“…Potential cost savings were shown on a system-wide basis in Canada 118 and Sweden. 116 There is a clear need for a large-scale cost study in the United States. Although 30-day hospital readmission rate is often used as a measure of care quality, this time period may be too short to adequately evaluate the effects of LAIs on quality and service utilization, and post hoc analyses have demonstrated that the benefits of LAIs are greater for patients who have been on treatment for longer periods of time.…”

Section: J Clin Psychiatry 2016;77 (Suppl 3)mentioning

confidence: 99%

“…These unexpected results may be partially explained by the high level of illness severity reflected in the large proportion of study patients who started LAI therapy as inpatients. In a study conducted in Sweden, 116 investigators modeled per-patient costs associated with several sequences of LAI or oral antipsychotics, including total costs associated with medical care, institutional care, and indirect costs. Treatment strategies that used LAIs had lower total 1-year treatment costs than strategies that included oral antipsychotic therapy.…”

Section: Effect Of Lais On Adherence and Costsmentioning

confidence: 99%

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia

Correll¹,

Citrome²,

Haddad³

et al. 2016

J. Clin. Psychiatry

286

276

View full text Add to dashboard Cite

Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden

Abstract: PP-LAI followed by OLZ-LAI was cost-effective in Sweden for chronic schizophrenia and cost-saving overall to the healthcare system.

Cited by 23 publications

References 71 publications

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study

Trends in the prescribing of antipsychotic medicines in Pakistan: implications for the future

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia

Contact Info

Product

Resources

About